Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHTYK3)

Drug Name
Ustekinumab Drug Info
Synonyms
6,6-Dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine; WR99210; WR-99210; 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE; 47326-86-3; BRN 0629517; WR 99210; 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-; WR-99,210; CHEMBL129788; BRL 6231; 1,6-Dihydro-6,6-dimethyl-1-(3-(2,4,5-trichlorophenoxy)-propoxy)-1,3,5-triazine-2 ,4-diamine; 1-(2',4',5'-Trichlorophenoxypropoxy)-1,2-dihydro-2,2-dimethyl-4,6-diamino-s-triazine; Stelara (TN)
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
Psoriasis EA90 Approved [2]
Psoriatic arthritis FA21 Approved [3]
Psoriasis vulgaris EA90 Phase 3 [1]
Inflammatory bowel disease DD72 Phase 2/3 [1]
Malaria 1F40-1F45 Investigative [4]
Cross-matching ID
TTD Drug ID
DMHTYK3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin-23 (IL23)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tildrakizumab DMLW9HG Plaque psoriasis EA90.0 Approved [6]
CNTO-1959 DMPC2QY Plaque psoriasis EA90.0 Approved [7]
Risankizumab DMM32GT Plaque psoriasis EA90.0 Approved [8]
BI 655066 DMBH4FL Chronic plaque psoriasis EA90.0 Phase 3 [9]
MK-3222 DMQBF7O Hairy cell leukaemia 2A82.2 Phase 3 [10]
Brazikumab DM4NWPE Crohn disease DD70 Phase 3 [11]
ABP 654 DM0GXWT Plaque psoriasis EA90.0 Phase 3 [12]
CNT0-1959 DMOR8SY Rheumatoid arthritis FA20 Phase 2 [7]
mRNA-2752 DMUKBI2 Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
AMG-139 DMEHOVF Crohn disease DD70 Phase 1 [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Interleukin-12 alpha (IL12A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Mirikizumab DM7R3N5 Ulcerative colitis DD71 Approved [15]
STA-5326 DMH4C3M Crohn disease DD70 Phase 2 [16]
Drug(s) Targeting Polypeptide deformylase (PDF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Proguanil DMBL79I Malaria 1F40-1F45 Approved [17]
Meprobamate DMHM93Y Anxiety Approved [18]
Pralatrexate DMAO80I Breast cancer 2C60-2C65 Approved [5]
Trimetrexate DMDEA85 Toxoplasmosis 1F57 Approved [19]
MCB-3837 DM0R4Z5 Malaria 1F40-1F45 Approved [18]
Chlorproguanil DM1IFGT Malaria 1F40-1F45 Approved [18]
LY333531 DMGMC8H Solid tumour/cancer 2A00-2F9Z Phase 2 [20]
Metoprine DM5GQD7 Advanced cancer 2A00-2F9Z Phase 2 [21]
Aminopterin DMQ9RBV leukaemia 2A60-2B33 Withdrawn from market [22]
2-Sulfhydryl-Ethanol DMJBO3D Discovery agent N.A. Investigative [23]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-12 alpha (IL12A) TTRTK6Y IL12A_HUMAN Not Available [5]
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [5]
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6885).
2 Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665-74.
3 Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May 19;323(19):1945-1960.
4 Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
5 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
7 Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
10 Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
11 Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.
12 Clinical pipeline report, company report or official report of Amgen
13 Clinical pipeline report, company report or official report of Moderna Therapeutics.
14 Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
17 Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
18 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
19 Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
20 Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
21 Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
22 Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
23 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.